## Courtney A Mcknight

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1766021/publications.pdf

Version: 2024-02-01

51

all docs

50 1,559 22 papers citations h-index

51

docs citations

h-index g-index

51 1632
times ranked citing authors

39

#	Article	IF	CITATIONS
1	Effectiveness of Respondent-Driven Sampling for Recruiting Drug Users in New York City: Findings from a Pilot Study. Journal of Urban Health, 2006, 83, 459-476.	3.6	199
2	Convergence of HIV seroprevalence among injecting and non-injecting drug users in New York City. Aids, 2007, 21, 231-235.	2.2	170
3	Doing harm reduction better: syringe exchange in the United States. Addiction, 2009, 104, 1441-1446.	3.3	107
4	A Randomized Trial of a Hepatitis Care Coordination Model in Methadone Maintenance Treatment. American Journal of Public Health, 2013, 103, e81-e88.	2.7	70
5	Social and Political Factors Predicting the Presence of Syringe Exchange Programs in 96 US Metropolitan Areas. American Journal of Public Health, 2007, 97, 437-447.	2.7	61
6	The transition from injection to non-injection drug use: long-term outcomes among heroin and cocaine users in New York City. Addiction, 2007, 102, 778-785.	3.3	59
7	Respondent-Driven Sampling in a Study of Drug Users in New York City: Notes from the Field. Journal of Urban Health, 2006, 83, 54-59.	3.6	58
8	Epidemiology of pain among outpatients in methadone maintenance treatment programs. Drug and Alcohol Dependence, 2013, 128, 161-165.	3.2	53
9	Persistence and Change in Disparities in HIV Infection Among Injection Drug Users in New York City After Large-Scale Syringe Exchange Programs. American Journal of Public Health, 2009, 99, S445-S451.	2.7	50
10	Associations Between Herpes Simplex Virus Type 2 and HCV With HIV Among Injecting Drug Users in New York City: The Current Importance of Sexual Transmission of HIV. American Journal of Public Health, 2011, 101, 1277-1283.	2.7	45
11	Risk factors for hepatitis C seropositivity among young people who inject drugs in New York City: Implications for prevention. PLoS ONE, 2017, 12, e0177341.	2.5	45
12	Using hepatitis C virus and herpes simplex virus-2 to track HIV among injecting drug users in New York City. Drug and Alcohol Dependence, 2009, 101, 88-91.	3.2	42
13	Incidence and prevalence of hepatitis c virus infection among persons who inject drugs in New York City: 2006–2013. Drug and Alcohol Dependence, 2015, 152, 194-200.	3.2	42
14	Perceptions of drug users regarding Hepatitis C screening and care: a qualitative study. Harm Reduction Journal, 2013, 10, 10.	3.2	41
15	Perceived discrimination among racial and ethnic minority drug users and the association with health care utilization. Journal of Ethnicity in Substance Abuse, 2017, 16, 404-419.	0.9	39
16	What's Community Got to Do With It? Implementation Models of Syringe Exchange Programs. AIDS Education and Prevention, 2005, 17, 68-78.	1.1	36
17	HIV infection during limited versus combined HIV prevention programs for IDUs in New York City: The importance of transmission behaviors. Drug and Alcohol Dependence, 2010, 109, 154-160.	3.2	36
18	Alternative kinship structures, resilience and social support among immigrant trans Latinas in the USA. Culture, Health and Sexuality, 2019, 21, 1-15.	1.8	32

#	Article	IF	CITATIONS
19	Diffusion of the D.A.R.E and Syringe Exchange Programs. American Journal of Public Health, 2006, 96, 1354-1358.	2.7	30
20	Longitudinal analysis of pain and illicit drug use behaviors in outpatients on methadone maintenance. Drug and Alcohol Dependence, 2015, 149, 285-289.	3.2	26
21	Consistent Estimates of Very Low HIV Incidence Among People Who Inject Drugs: New York City, 2005–2014. American Journal of Public Health, 2016, 106, 503-508.	2.7	23
22	Herpes Simplex Virus-2 and HIV Among Noninjecting Drug Users in New York City. Sexually Transmitted Diseases, 2007, 34, 923-927.	1.7	22
23	Cost-effectiveness of hepatitis C screening and treatment linkage intervention in US methadone maintenance treatment programs. Drug and Alcohol Dependence, 2018, 185, 411-420.	3.2	22
24	Transitions from injecting to non-injecting drug use: Potential protection against HCV infection. Journal of Substance Abuse Treatment, 2014, 46, 325-331.	2.8	20
25	HSV-2 Co-Infection as a Driver of HIV Transmission among Heterosexual Non-Injecting Drug Users in New York City. PLoS ONE, 2014, 9, e87993.	2.5	18
26	Public Funding of US Syringe Exchange Programs. Journal of Urban Health, 2004, 81, 118-121.	3.6	17
27	A Perfect Storm: Crack Cocaine, HSV-2, and HIV Among Non-Injecting Drug Users in New York City. Substance Use and Misuse, 2014, 49, 783-792.	1.4	17
28	The New York 911 Good Samaritan Law and Opioid Overdose Prevention Among People Who Inject Drugs. World Medical and Health Policy, 2017, 9, 318-340.	1.6	16
29	What predicts which metropolitan areas in the USA have syringe exchanges?. International Journal of Drug Policy, 2003, 14, 417-424.	3.3	15
30	Can intranasal drug use reduce HCV infection among injecting drug users?. Drug and Alcohol Dependence, 2011, 119, 201-206.	3.2	12
31	Viral Hepatitis Among Drug Users in Methadone Maintenance: Associated Factors, Vaccination Outcomes, and Interventions. Journal of Addictive Diseases, 2014, 33, 322-331.	1.3	12
32	Education and counseling in the methadone treatment setting improves knowledge of viral hepatitis. Journal of Substance Abuse Treatment, 2014, 46, 528-531.	2.8	12
33	Gender and Age Patterns in HSV-2 and HIV Infection Among Non-Injecting Drug Users in New York City. Sexually Transmitted Diseases, 2010, 37, 637-643.	1.7	12
34	Providing ART to HIV Seropositive Persons Who Use Drugs: Progress in New York City, Prospects for "Ending the Epidemic― AIDS and Behavior, 2016, 20, 353-362.	2.7	11
35	Syringe exchange, injecting and intranasal drug use. Addiction, 2010, 105, 155-158.	3.3	10
36	HSV-2 Infection as a Cause of Female/Male and Racial/Ethnic Disparities in HIV Infection. PLoS ONE, 2013, 8, e66874.	2.5	10

#	Article	IF	CITATIONS
37	What happened to the HIV epidemic among nonâ€injecting drug users in New York City?. Addiction, 2017, 112, 290-298.	3.3	9
38	Racial/Ethnic Disparities at the End of an HIV Epidemic: Persons Who Inject Drugs in New York City, 2011â€"2015. American Journal of Public Health, 2017, 107, 1157-1163.	2.7	9
39	Heterosexual male and female disparities in HIV infection at the end of an epidemic: HIV infection among persons who inject drugs in New York City, 2001–2005 and 2011–2015. Drug and Alcohol Dependence, 2018, 185, 391-397.	3.2	9
40	From Long-Term Injecting to Long-Term Non-Injecting Heroin and Cocaine Use: The Persistence of Changed Drug Habits. Journal of Substance Abuse Treatment, 2016, 71, 48-53.	2.8	8
41	Hepatitis C incidence and prevalence among Puerto Rican people who use drugs in New York City. Global Public Health, 2020, 15, 1789-1799.	2.0	7
42	Modeling HIV transmission among persons who inject drugs (PWID) at the "End of the HIV Epidemic― and during the COVID-19 pandemic. Drug and Alcohol Dependence, 2022, 238, 109573.	3.2	6
43	Use of the "NYC Condom―among People Who Use Drugs. Journal of Urban Health, 2014, 91, 547-554.	3.6	5
44	Thick trust, thin trust, social capital, and health outcomes among trans women of color in New York City. International Journal of Transgender Health, 2022, 23, 1-18.	2.3	5
45	Prescription opiate analgesics, heroin, HIV and HCV among persons who inject drugs in New York City, 2016-2018. Drug and Alcohol Dependence, 2019, 204, 107459.	3.2	4
46	Decline in Herpes Simplex Virus Type 2 Among Non-Injecting Heroin and Cocaine Users in New York City, 2005 to 2014: Prospects for Avoiding a Resurgence of Human Immunodeficiency Virus. Sexually Transmitted Diseases, 2017, 44, 85-90.	1.7	2
47	Injection and Heterosexual Risk Behaviors for HIV Infection Among Non-gay Identifying Men Who Have Sex with Men and Women. AIDS and Behavior, 2019, 23, 3315-3323.	2.7	2
48	Is your syringe services program cost-saving to society? A methodological case study. Harm Reduction Journal, 2021, 18, 126.	3.2	2
49	Will "Combined Prevention" Eliminate Racial/Ethnic Disparities in HIV Infection among Persons Who Inject Drugs in New York City?. PLoS ONE, 2015, 10, e0126180.	2.5	1
50	Recurrent Injecting Drug Use as a Mediator between Psychiatric Disorder and Non-Fatal Overdose. Substance Use and Misuse, $0$ , $1$ - $9$ .	1.4	0